Allergan PLC. (NYSE:AGN) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. reduced its stake in shares of Allergan PLC. (NYSE:AGN) by 4.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,668 shares of the company’s stock after selling 1,711 shares during the period. Oppenheimer & Co. Inc.’s holdings in Allergan PLC. were worth $9,000,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Veritas Asset Management LLP bought a new position in shares of Allergan PLC. during the first quarter valued at approximately $761,339,000. Iridian Asset Management LLC CT raised its position in shares of Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after buying an additional 751,848 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Allergan PLC. during the first quarter valued at approximately $124,255,000. First Manhattan Co. raised its position in shares of Allergan PLC. by 193.3% in the first quarter. First Manhattan Co. now owns 497,793 shares of the company’s stock valued at $114,646,000 after buying an additional 328,062 shares during the last quarter. Finally, Schroder Investment Management Group raised its position in Allergan PLC. by 133.3% in the first quarter. Schroder Investment Management Group now owns 417,948 shares of the company’s stock worth $100,225,000 after buying an additional 238,796 shares in the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.

Shares of Allergan PLC. (NYSE:AGN) opened at 223.99 on Friday. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The firm has a 50-day moving average price of $243.31 and a 200-day moving average price of $238.68. The stock has a market cap of $74.88 billion, a PE ratio of 6.82 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the firm earned $3.35 EPS. On average, analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.25%. Allergan PLC.’s payout ratio is 9.95%.

ILLEGAL ACTIVITY NOTICE: “Allergan PLC. (NYSE:AGN) Shares Sold by Oppenheimer & Co. Inc.” was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/oppenheimer-co-inc-sells-1711-shares-of-allergan-plc-nyseagn-updated-updated.html.

AGN has been the subject of a number of recent research reports. Citigroup Inc. reissued a “focus list” rating and set a $261.27 price target (up from $184.50) on shares of Allergan PLC. in a research report on Friday, April 21st. Royal Bank Of Canada raised their price objective on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) cut shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a research note on Wednesday, May 10th. UBS AG reissued a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a research note on Monday, May 15th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply